Zolbetuximab Loses GLEAM In Pancreatic Cancer

Rising CLDN18.2 Competition From China

 
• By Lisa Takagi
  
zolbetuximab p2 pancreatic
Zolbetuximab's P2 failure for pancreatic cancer treatment may shift the global competition, which largely takes place in China. (Shutterstock)

More from Anticancer

More from Japan